NeoPhore Limited, a cancer immuno-oncology company, announced yesterday that it has named Dr John Haurum as its new non-executive director with immediate effect.
Dr Haurum was earlier chief executive officer of F-star. Before F-star, he was VP Research at ImClone Systems, prior to this he was the CSO and Co-founder of Symphogen. He is currently executive chairman of the board at Synklino.
Robert James, chairman of NeoPhore, said, 'I would like to welcome John to the Neophore board. John has an excellent track record of building and growing companies in the biotech industry and his expertise and scientific understanding of the IO space will be invaluable as we maximise the potential of our platform.'
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA